Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $9.63 USD
Change Today +0.40 / 4.33%
Volume 116.8K
VCYT On Other Exchanges
Symbol
Exchange
Berlin
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

veracyte inc (VCYT) Snapshot

Open
$9.29
Previous Close
$9.23
Day High
$9.65
Day Low
$9.10
52 Week High
06/27/14 - $18.00
52 Week Low
11/14/14 - $6.01
Market Cap
217.2M
Average Volume 10 Days
88.0K
EPS TTM
$-1.36
Shares Outstanding
22.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERACYTE INC (VCYT)

Related News

No related news articles were found.

veracyte inc (VCYT) Related Businessweek News

No Related Businessweek News Found

veracyte inc (VCYT) Details

Veracyte, Inc. operates as a molecular diagnostics company in the United States. It operates in the field of molecular cytology with genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early stage in patient care. The company offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers, which comprise the genomic tests for medullary thyroid cancer and BRAF V600E mutation status. It also develops a product to preoperatively identify idiopathic pulmonary fibrosis among patients presenting with a suspected interstitial lung disease; and the Percepta Bronchial Genomic Classifier, a lung cancer test that would identify patients with non-diagnostic bronchoscopy results whose nodules are at low risk of being cancerous. Veracyte, Inc. serves endocrinologists; radiologists; and ear, nose, and throat physicians. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

167 Employees
Last Reported Date: 03/25/15
Founded in 2006

veracyte inc (VCYT) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $425.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $300.0K
Chief Operating Officer
Total Annual Compensation: $341.2K
Compensation as of Fiscal Year 2014.

veracyte inc (VCYT) Key Developments

Veracyte, Inc. Initiates Launch of Percepta™ Bronchial Genomic Classifier to Improve Lung Cancer Diagnosis

Veracyte, Inc. announced the launch of its Percepta™ Bronchial Genomic Classifier, a new genomic test to resolve ambiguity in lung cancer diagnosis. The company will soon begin testing patient samples in its CLIA-certified laboratory, with the Percepta test now available to a limited number of institutions around the country. The Percepta test is designed to reduce the number of invasive biopsies and other procedures that can follow when suspicious lung nodules are found on computerized tomography (CT) scans. The test is used when results from a bronchoscopy - a common nonsurgical procedure to evaluate lung nodules - are non-diagnostic, meaning that cancer cannot be ruled out. Data from a prospective, multicenter clinical validation study previously demonstrated the Percepta test's ability to identify patients whose lung nodules are at low risk of malignancy so that they can be monitored with CT scans in lieu of invasive diagnostic procedures. Veracyte's test comprises a 23-gene molecular classifier that uses proprietary "field of injury" technology to detect molecular changes that occur in the epithelial cells lining the lung's respiratory tract in response to smoking - the cause of 85-90% of lung cancers. These changes can be detected in cells obtained from standard cytology brushings taken during bronchoscopy from the proximal airway, and indicate the presence of malignancy or disease processes from distant sites in the lung.

Veracyte, Inc. and GE Announce Research Collaboration

Veracyte, Inc. and GE announced a research collaboration to develop new solutions that can improve disease diagnosis. Veracyte will collaborate with GE Ventures, GE Healthcare, and the GE Global Research Center to explore the feasibility of combining Veracyte's genomic technology with GE Healthcare's digital imaging technology. Through the agreement, Veracyte and GE aim to identify features from raw imaging data that, when combined with genomic information, have the potential to elucidate useful, new information to further address unmet clinical needs.

Veracyte, Inc. Announces Executive Changes

Veracyte, Inc. announced that in connection with his appointment as Senior Vice President, Strategic Finance and Operations, on April 6, 2015, Duncan T. Powell ceased to serve as the Principal Accounting Officer. Also on April 6, 2015, the Board of Directors of the company appointed Shelly D. Guyer, the company's Chief Financial Officer, to serve in the additional position of principal accounting officer. Ms. Guyer has served as the company's Chief Financial Officer since April 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VCYT:US $9.63 USD +0.40

VCYT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Genomic Health Inc $30.59 USD -0.29
Laboratory Corp of America Holdings $126.93 USD +0.55
Response Genetics Inc $0.29 USD -0.002
Rosetta Genomics Ltd $3.72 USD +0.06
Trovagene Inc $8.80 USD -0.13
View Industry Companies
 

Industry Analysis

VCYT

Industry Average

Valuation VCYT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.4x
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERACYTE INC, please visit www.veracyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.